Diseases of the Digestive System - Liver | Diseases of the Digestive System - Pancreas | Diseases of the Digestive System - Small Intestines, Large Intestines & Rectum, Phase III

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Volunteers
Health Professionals

What is the purpose of this trial?

The main objective of the study is to evaluate the effect of daily oral administration of 80mg elafibranor on cholestasis (impairment of bile formation and/or bile accumulation) in patients with PBC and inadequate response or intolerance to Ursodeoxycholic Acid (UCDA).

Trial with
Genfit
Ages
18 years - 75 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Suzie Christopher

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Marina Silveira, MD
Associate Professor of Medicine (Digestive Diseases)

Sub-Investigators

Last Updated
02/23/2024
Study HIC
#2000030228